耀才团队: 大市将挑战250天线即25,786水平
耀才证券研究部团队称,欧美股市隔晚(24日)全线向上,美国批准以新冠肺炎康复者的血浆作为治疗方法,有助减低死亡率达三成,市场憧憬疫情尽快受控,标指及纳指盘中双双破顶,标指高见3,432点,纳指一度见11,462点,但仍有个案指人类可以重覆染病,投资者开始调整各个板块之估值,收市时科技股轻微回稳,旧经济股表现较强。港股ADR有所回吐,但美国贸易办公室发声明指中美双方今日(25日)将进行通话,双方亦认同取得正面进展,以及将采取更多行动确保首阶段协议成功,大市气氛乐观,加上本地疫情有受控现象,将有条件挑战250天线即25,786水平。
从技术上看,恒指上周五(21日)重上25,000点关口,完全收复上周四(20日)的跌幅。短线而言,指数仍是上落待变之格局,而本周五为即月期指结算,一日恒指仍徘徊於100天及250天线之间,即24,500点至25,800点内,後市仍缺乏明确方向。
(笔者为证监会持牌人)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.